triumph 1 trial retatrutide TRIUMPH-1 results: Retatrutide, the triple agonist. Significant weight loss ( 28.3% average loss at 80 weeks). It has potential to transform obesity treatment with results comparable to… Looking forward to when #retatrutide's

As of April 2026, there is no FDA-approved generic Ozempic

In 2024, it posted strong sales and core profit growth, driven by specialty medicines and robust progress through its Phase III development pipeline

Suspected adverse reactions should be reported to the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk)

When asked what theyd be willing to give up to afford a GLP-1 prescription, 38% said dining out or takeout, 24% said travel or leisure, and 22% said streaming subscriptions

The recent announcement comes in light of Patientory being named a 2024 Health Equity Business Accelerator Participant , just after their early-funding stage generated investments of over $325,000